Can the FDA accelerate its current new pharmaceutical and or biologic approval processes without compromising patient safety?

Can the FDA accelerate its current new pharmaceutical and or biologic approval processes without compromising patient safety?

2. FDA may also grant accelerated approval based on an effect on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit (i.e., an intermediate clinical endpoint).

What was the first drug to receive FDA accelerated approval?

Almost immediately after the new rule was proposed, the FDA granted the first official Accelerated Approval, on June 22, 1992, for zalcitabine, another NARTI for the treatment of HIV/AIDS.

What is the difference between Fast Track and accelerated approval?

From Accelerated Approval and Priority Review to Fast Track and Breakthrough. Recognizing the difference between accelerated approval and priority review is easy. Accelerated approval is based on surrogate or intermediate endpoints followed by confirmatory study(ies) and a priority review is six months rather than ten.

Is accelerated approval full approval?

The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.

What is FDA accelerated approval program?

The accelerated approval program, which applies to serious or life-threatening diseases or conditions, allows for an earlier submission or approval based on substantial evidence of an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or a clinical endpoint that can be measured …

What does accelerated approval Mean FDA?

What is the FDA Accelerated Approval program?

Mindful of the fact that it may take an extended period of time to measure a drug’s intended clinical benefit, in 1992 FDA instituted the Accelerated Approval regulations. These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint.

What are the possible adverse reactions to Zelboraf?

Anaphylaxis and other serious hypersensitivity reactions can occur during treatment and upon re-initiation of treatment with ZELBORAF. Severe hypersensitivity reactions included generalized rash and erythema, hypotension, and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome).

How does the FDA decide if a drug is approved?

For example, instead of having to wait to learn if a drug actually extends survival for cancer patients, the FDA may approve a drug based on evidence that the drug shrinks tumors, because tumor shrinkage is considered reasonably likely to predict a real clinical benefit.

What is a surrogate endpoint for accelerated approval?

A surrogate endpoint used for accelerated approval is a marker – a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit.